New Peptides and Proteins Study Findings Recently Were Reported by Researchers at University of Portsmouth (Strategies to deliver peptide drugs to the brain)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Peptides and Proteins. According to news reporting originating in Portsmouth, United Kingdom, by NewsRx journalists, research stated, "Neurological diseases such as neurodegeneration, pain, psychiatric disorders, stroke, and brain cancers would greatly benefit from the use of highly potent and specific peptide pharmaceuticals. Peptides are especially desirable because of their low inherent toxicity."
The news reporters obtained a quote from the research from the University of Portsmouth, "The presence of the blood brain barrier (BBB), their short duration of action, and their need for parenteral administration limits their clinical use. However, over the past decade there have been significant advances in delivering peptides to the central nervous system. Angiopep peptides developed by Angiochem (Montreal, Canada), transferrin antibodies developed by ArmaGen (Santa Monica, USA), and cell penetrating peptides have all shown promise in delivering therapeutic peptides across the BBB after intravenous administration. Noninvasive methods of delivering peptides to the brain include the use of chitosan amphiphile nanoparticles for oral delivery and nose to brain strategies. The uptake of the chitosan amphiphile nanoparticles by the gastrointestinal epithelium is important for oral peptide delivery."
According to the news reporters, the research concluded: "Finally protecting peptides from plasma degradation is integral to the success of most of these peptide delivery strategies."
For more information on this research see: Strategies to deliver peptide drugs to the brain. Molecular Pharmaceutics, 2014;11(4):1081-93. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
Our news correspondents report that additional information may be obtained by contacting A. Lalatsa, Dept. of Pharmaceutics, School of Pharmacy and Biomedical Sciences, University of Portsmouth , St Michael's Building 505, White Swan Road, Portsmouth, PO1 2DT, UK. Additional authors for this research include A.G. Schatzlein and I.F Uchegbu (see also Peptides and Proteins).
Keywords for this news article include: Europe, Portsmouth, Amino Acids, Nanoparticle, United Kingdom, Nanotechnology, Emerging Technologies, Peptides and Proteins.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC